A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of two doses of ACT-128800, an oral S1P1 receptor agonist, administered up to twenty-eight weeks in patients with moderate to severe chronic plaque psoriasis

ACTELION Pharmaceuticals Ltd0 个研究点目标入组 320 人开始时间: 2011年1月27日最近更新: 2013年10月21日

试验速览

暂无简介。

•Adult males and females aged 18 to 60 years (inclusive) with moderate to severe plaque psoriasis who require systemic treatment.
•Patients achieving at least PASI50 at Week 16 are eligible to continue participating in the study up to week 28 (maintenance period).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 320
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Patients with other forms of psoriasis and patients who are currently treated for autoimmune disorders other than psoriasis.
•Systemic or topical treatments for psoriasis other than emollients.
•Ongoing bacterial, viral or fungal infections.
•History or presence of malignancy.
•Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.

发起方